超声内镜引导下顺行干预治疗良性胆肠吻合口狭窄的长期结局
本研究纳入2013年11月至2021年11月间34例良性胆肠吻合口狭窄(BES)患者,随访超过1年,评估超声内镜引导下顺行干预(EUS-AI)的长期结局。中位随访56.7个月,狭窄缓解率50%(17/34),多因素分析显示合并胆管结石与狭窄缓解显著相关(OR 9.473,95%CI 1.66-53.98,P=0.01)。狭窄复发率33%,中位支架移除至复发时间31.2个月;4例因复发性胆管炎行手术;25%基于FIB-4分级进展为肝纤维化,随访期间无胆管炎者未见肝纤维化进展。
要点
- EUS-AI治疗良性胆肠吻合口狭窄的长期狭窄缓解率为50%(17/34),复发率33%。
- 合并胆管结石与狭窄缓解显著相关(OR 9.473,95%CI 1.66-53.98,P=0.01)。
- 中位随访56.7个月,25%患者基于FIB-4分级进展为肝纤维化。
核心结论
- EUS-AI取得了可接受的长期临床结局,对于常规方法难以治疗的患者,可在手术治疗前作为可选的替代治疗。
研究设计与样本
- 回顾性识别2013年11月至2021年11月间因良性胆肠吻合口狭窄接受EUS-AI并随访超过1年的34例患者,中位随访56.7个月。
主要发现
- 狭窄缓解17/34例(50%)。
- 多因素分析显示胆管结石存在与狭窄缓解显著相关(OR 9.473,95%CI 1.66-53.98,P=0.01)。
- 狭窄复发率33%,中位支架移除至复发时间31.2个月。
- 4例因复发性胆管炎行手术。
- 中位随访56.7个月期间,25%患者基于FIB-4指数分级进展为肝纤维化;随访期间无胆管炎者未见肝纤维化进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Bilioenteric anastomotic stricture (BES) is a well-known adverse event after bilioenterostomy. Recently, EUS-guided antegrade intervention (EUS-AI) has been developed for cases that are difficult to treat by balloon enteroscopy-assisted ERCP. However, no data are available on the long-term outcomes after EUS-AI. The main goal of the present study was to clarify the long-term outcomes of EUS-AI in such patients. METHODS: Between November 2013 and November 2021, 34 patients who were followed for more than 1 year after EUS-AI for BES were identified. The primary endpoint was the rate of stricture resolution. Secondary endpoints were factors associated with stricture resolution, rate of BES recurrence, rate of conversion to surgery, and rate of hepatic fibrosis progression during follow-up. RESULTS: The median follow-up period was 56.7 months. Stricture resolution was achieved in 17 of 34 patients (50%). A multivariate analysis confirmed that the presence of bile duct stones (odds ratio, 9.473; 95% confidence interval, 1.66-53.98; P = .01) was significantly associated with stricture resolution. The stricture recurrence rate was 33%, and the median time from stent removal to recurrence was 31.2 months. Four patients underwent surgery because of recurrent cholangitis. During the median follow-up period of 56.7 months, 25% progressed to hepatic fibrosis based on the Fibrosis-4 index grade. Interestingly, patients without cholangitis during follow-up did not show progression of hepatic fibrosis. CONCLUSIONS: EUS-AI has achieved acceptable long-term clinical outcomes. EUS-AI can be a viable alternative treatment of choice before surgical treatment in patients who are difficult to treat by conventional approaches.
引用
- Nagai K, Mukai S, Abe M, et al. Long-term outcomes after EUS-guided antegrade intervention for benign bilioenteric anastomotic stricture. Gastrointest Endosc. 2023. PMID: 37562548. doi:10.1016/j.gie.2023.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。